The peripheral blood samples (5 mL) were collected from 22 healthy donors. Individuals with cancer, allergic diseases, immune-compromised conditions, diabetes or other infectious diseases such as HBV, HCV and HIV infection were excluded. After sample collection, PBMCs were isolated by density gradient centrifugation. To develop MDMs, the monocytes were purified using anti-CD14 magnetic beads (Miltenyi Biotec, USA) and the purified monocytes were cultured in RPMI 1640 medium contains 10% Human serum and 0.05% Glutamine (Sigma, USA) for 7 days at 5% CO2 and 37 °C14. The MDMs were identified by morphologic observation and flow cytometric analysis followed by anti-CD68 staining.
Copyright and License information: The Author(s) ©2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this
article to respond.